Inclusion Criteria:
1. Ability to provide written informed consent and HIPAA authorization
2. Patients deemed eligible and willing to receive a COVID-19 vaccine by treating physician per standard of care.
3. Subjects must be ≥ 18 years old at the time of consent.
4. Diagnosis of cancer and fall into one of the groups below:
1. Group 1: Patients with solid tumors receiving courses of cytotoxic therapy.
2. Group 2: Patients with hematological cancers receiving courses of cytotoxic chemotherapy.
3. Group 3: Patients with solid tumors receiving tyrosine kinase inhibitors (TKIs) or other targeted therapies, but not cytotoxic regimens within 3 months.
4. Group 4: Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months.
5. Group 5: Patients receiving immune checkpoint inhibitors.
6. Group 6: Patients who underwent allogeneic stem cell transplant within 12 months.
7. Group 7: Patients who underwent cellular therapy, including Chimeric antigen receptor t-cells (CAR-T) cells or t-cells with engineered t-cell receptors (TCRs) within 12 months.
8. Group 8: Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches.
9. Group 9: Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).
10. Group 10: Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants
11. Group 11: Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants
12. Group 12: Patients who have a cancer diagnosis but do not fall into group 1-11
3. Estimated survival of 8 weeks or more following enrollment on the study.
Exclusion Criteria:
1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active COVID-19 infection or influenza-like-illness. If subjects have previously tested positive for COVID-19 infection, they are eligible to participate in this study after 90 days
2. Unwilling or unable to follow protocol requirements.
